Erratum to Safety and immunogenicity of a novel cold-adapted modified-live equine influenza virus vaccine Aust Vet J 2014;92:450-457. DOI: 10.1111/avj.12248;Safety and immunogenicity of a novel cold-adapted modified-live equine influenza virus vaccine

Australian Veterinary Journal

Volumn 92, Issue 11, 2014, Pages 450-457

  Tabynov, K ^a   Kydyrbayev, Z ^a   Ryskeldinova, S ^a   Assanzhanova, N ^a   Kozhamkulov, Y ^a   Inkarbekov, D ^a   Sansyzbay, A ^a  

^a Ministry of Education and Science of the Republic of Kazakhstan   (Kazakhstan)

Author keywords

Cold adapted vaccine; Equine influenza virus; Horses; Immunogenicity

Indexed keywords

EQUIDAE; EQUINE INFLUENZA VIRUS;

INFLUENZA VACCINE; VIRUS ANTIBODY;

ANIMAL; ANIMAL EUTHANASIA; BLOOD; CELLULAR IMMUNITY; CHICK EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GERMFREE ANIMAL; HORSE; HORSE DISEASES; HUMORAL IMMUNITY; IMMUNOLOGY; INFLUENZA A VIRUS (H3N8); INTRANASAL DRUG ADMINISTRATION; MALE; NASOPHARYNX; ORTHOMYXOVIRIDAE INFECTIONS; PREGNANCY; STANDARDS; VETERINARY; VIROLOGY; VIRUS SHEDDING;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CHICK EMBRYO; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUTHANASIA, ANIMAL; FEMALE; HORSE DISEASES; HORSES; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INFLUENZA A VIRUS, H3N8 SUBTYPE; INFLUENZA VACCINES; MALE; NASOPHARYNX; ORTHOMYXOVIRIDAE INFECTIONS; PREGNANCY; SPECIFIC PATHOGEN-FREE ORGANISMS; VIRUS SHEDDING;

EID: 84911497898     PISSN: 00050423     EISSN: 17510813     Source Type: Journal    
DOI: 10.1111/avj.12300     Document Type: Erratum

References (25)

1. Cullinane A, Elton D, Mumford J. Equine influenza: surveillance and control. Influenza Other Resp Viruses 2010;6:339-344.
2. Paillot R, Hannant D, Kydd JH etal. Vaccination against equine influenza: Quid novi? Vaccine 2006;24:4047-4061.
3. Morley PS, Townsend HG, Bogdan JR etal. Efficacy of a commercial vaccine for preventing disease caused by influenza virus infection in horses. J Am Vet Med Assoc 1999;215:61-66.
4. Mumford JA, Wood J. Establishing an acceptable threshold for equine influenza vaccines. Dev Biol Stand 1992;79:137-146.
5. Heldens JGM, Pouwels HGW, van Loon AAWM. Efficacy and duration of immunity of a combined equine influenza and equine herpesvirus vaccine against challenge with an American-like equine influenza virus (A/equi-2/Kentucky/95). Vet J 2004;167:150-157.
6. Heldens JGM, Patel JR, Chanter N etal. Veterinary vaccine development from an industrial perspective. Vet J 2008;178:7-20.
7. Hannant D, Mumford JA, Jesset DM. Duration of circulating antibody and immunity following infection with equine influenza. Vet Rec 1988;122:125-128.
8. Holmes DF, Lamb LM, Coggins L etal. Live temperature senseitive equine-2 influenza A virus vaccine: production and efficacy in experimental ponies. In: Equine infectious diseases VI. Proceedings of the Sixth International Conference, Newmarket, UK, 7-11 July 1991:253-258.
9. Chambers TM, Holland RE, Tudor LR etal. A new modified live equine influenza virus vaccine: phenotypic stability, restricted spread and efficacy against heterologous virus challenge. Equine Vet J 2001;33:630-636.
10. Townsend HG, Penner SJ, Watts TC etal. Efficacy of a cold-adapted, intranasal, equine influenza vaccine: challenge trials. Equine Vet J 2001;33:637-643.
11. Kittel C, Sereinig S, Ferko B etal. Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology 2004;324:67-73.
12. Minke JM, El-Hage CM, Tazawa P etal. Evaluation of the response to an accelerated immunisation schedule using a canarypox-vectored equine influenza vaccine, shortened interdose intervals and vaccination of young foals. Aust Vet J 2011;89:137-139.
13. Minke JM, Toulemonde CE, Coupier H etal. Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge. Am J Vet Res 2007;68:213-219.
14. Sultankulova KT, Sandybayev NT, Chervyakova OV etal. New recombinant strain A/HK/Astana/6:2/2010 for prophylaxis of A/H5N1 influenza. Biotechnol Res Bull 2012;1:005-014.
15. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938;27:493-497.
16. World Organisation for Animal Health (OIE). Chapter 2.5.7: equine influenza terrestrial manual. In: OIE manual of diagnostic tests and vaccines for terrestrial animals. Vol. 2. 6th edn. OIE, Paris, 2008:877-881.
17. Soboll G, Horohov DW, Aldridge BM etal. Regional antibody and cellular immune responses to equine influenza virus infection, and particle mediated DNA vaccination. Vet Immunol Immunopathol 2003;94:47-62.
18. Kydyrmanov AI, Kumekbayeva ZhZh, Karamendin KO etal. [Isolation of an influenza virus A (H3N8) from horses in Kazakhstan in 2007]. Veterinarya 2009;5:52-54 (in Russian).
19. Tabynov K, Kydyrbayev Zh, Ryskeldinova Sh etal. Duration of the protective immune response after prime and booster vaccination of yearlings with a live modified cold-adapted viral vaccine against equine influenza. Vaccine 2014;32:2965-2971.
20. World Organisation for Animal health (OIE). OIE Expert Surveillance Panel on Equine Influenza Vaccine Composition, OIE Headquarters, 4 March 2013. http://www.oie.int Accessed July 2014.
21. Tabynov KK, Kydyrbayev ZhK, Sansyzbay AR etal. [Experimental study of safety and immunogenicity of cold-adapted reassortant strain A/HK/Otar/6:2/2010 of influenza virus in horses]. Act Issues Vet Biol 2012;3:87-99 (in Russian).
22. Assanzhanova NN, Tabynov KK, Kydyrbayev ZhK etal. [Studying safety and immunogenicity of clones of reassortant influenza virus strain A/HK/Otar/6:2/2010 (H3N8) on the model of laboratory animals]. Biotechnol Theory Pract 2012;1: 69-76 (in Russian).
23. TM I.N. vaccine in horses. J Equine Vet Sci 2000;20:8-10.
24. Minke JM, Audonnet JC, Fischer L. Equine viral vaccines: the past, present and future. Vet Res 2004;35:425-443.
25. Hannant D, Jessett DM, O'Neill T etal. Nasopharyngeal, tracheobronchial, and sytemic immune responses to vaccination and aerosol infection with equine-2 influenza A virus (H3N8). In: Equine infectious diseases V. Proceedings of the Fifth International Conference, Lexington, KY, 1987:66-73.